Cooperative epigenetic modulation by cancer amplicon genesHematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBeyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialDonor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.Hodgkin lymphoma, version 2.2015.High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probeInterleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys.Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialDonor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyImpact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusGraft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioRecovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantationAllogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Inhibition of DNA glycosylases via small molecule purine analogsGraft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Antibody-directed therapies for hematological malignancies.Rituximab: mechanism of action and resistance.New treatment options have changed the survival of patients with follicular lymphoma.Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.Non-myeloablative transplantation.Rituximab resistance.
P50
Q24608701-6C5916AC-4E68-499C-9DBE-2B7C9AAC7107Q24685958-DE551DFF-E28A-479F-B0C2-1F896AC821BEQ30275206-4CD15430-DFE4-4C03-8458-24D1330778ECQ30486842-DB46B33A-0414-49CA-892A-BB1516E9BEA1Q30543777-483DD936-AB06-4347-9768-A3A60FE0A6EAQ30558271-FA9396DC-19BB-4154-BFF6-8AF8D5B187BDQ30769157-11F5819C-87E7-42C8-87D5-42F495A74110Q31111842-C7C6975F-5535-4AE9-85C0-055F71076075Q33346202-8E0890CD-F841-4D3D-A874-44E86F474DA9Q33348936-03786743-2DC3-4D3E-B575-256E9895EE23Q33396929-A9F5ABEC-2E7E-4BF4-A9F2-8FC873C8F990Q33419003-737F9242-7B7C-443A-A057-A8BB5FA75BAFQ33424056-E02B6E73-B5F6-4745-B4D8-435BE68EE24CQ33605275-90662E96-37FB-44BC-9A94-E51D19FFB626Q33653406-8A3F4459-3CC8-4B38-BC2C-B2567B745B62Q33677489-53E888E3-849A-455A-A9F3-27BCE6430A19Q33990856-D2EB609F-EB4B-41AB-A3EC-0E35D054D6D0Q34022682-8C00AF5D-6E14-45EA-8314-8B4C5538AC2BQ34046263-02A4D04C-8176-4008-BACC-BE2BC251ABC6Q34106362-E51BE7AD-E331-4642-8CE1-8131823E106FQ34106817-1E32D06A-D871-45D5-9DBE-41DC0B9BEFADQ34186689-224B87D8-0937-42E7-AEDD-4CDB93857327Q34202277-2D9BDFEB-F985-4856-BB2B-71A12D35077FQ34208618-0FC1D801-5B1A-4B8A-8802-62CFA7B445BDQ34216815-E1DC7715-7FAB-4D62-AB2E-B946B3CB5BF3Q34260505-86B9B682-E8FD-4B83-B7FE-8B1B76A19927Q34272554-6403DAEA-2D3F-4DA9-92D8-886124666FFCQ34325329-DBEE953C-7EB8-4A14-AC9F-817400938827Q34370320-EA706235-E17F-478B-A19F-EB20C9A5E632Q34392708-CD2B3491-CA67-424C-83B1-1A059431F4C0Q34404171-5F99FDAE-1FD7-41E8-8A07-826B155BFBACQ34508495-DA09FA56-8EB0-47EA-9B5B-BB538A745F6FQ34528335-452605A5-C9CC-48BC-951E-F817DF033001Q34561857-80076129-3547-46FB-BCE9-AF3E75EF2695Q34583041-89C9453C-06A3-46B0-BF4F-E8E3AEB72474Q34630152-54F99726-8CC6-4FE9-B206-F4272E4BA8B2Q34725757-129C0ADE-7EE0-413E-8417-37FE01323791Q34859147-C2C9086A-B515-458C-834C-D2B9212895A4Q35006669-4C476CA1-B14C-45E9-A169-C6D06BB06339Q35041270-ADC4BF41-A2E6-4837-9CF3-FC45FFFBD17F
P50
description
oncoloog
@nl
name
David G. Maloney
@ast
David G. Maloney
@en
David G. Maloney
@es
David G. Maloney
@nl
type
label
David G. Maloney
@ast
David G. Maloney
@en
David G. Maloney
@es
David G. Maloney
@nl
prefLabel
David G. Maloney
@ast
David G. Maloney
@en
David G. Maloney
@es
David G. Maloney
@nl
P106
P21
P31
P569
1954-11-25T00:00:00Z